Th1-Inducing CpG–STING Adjuvant for IgE Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants primarily induce humoral immunity (Th2 adjuvants) and are less effective in inducing cell-mediated immunity (Th1 adjuvants) necessary for cancer and allergy therapies, with STING agonists potentially causing IgE side effects.
Innovation Solution
Combining CpG oligonucleotides with STING agonists to synergistically induce a Th1 immune response, suppressing IgE production and enhancing cell-mediated immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If STING agonists are used alone, then humoral immunity is induced, but IgE side effects occur and cell-mediated immunity is insufficient
Solution Approach 1:
The patent combines CpG oligonucleotides (TLR9 agonists) with STING agonists to create a dual-agonist adjuvant system. This merging of two different immunostimulatory pathways synergistically enhances Th1-type cell-mediated immunity while suppressing the harmful IgE production that occurs with STING agonists alone, thereby resolving both the harmful effect and the insufficiency simultaneously
2Productivity
If Th2 adjuvants are used, then humoral immunity is enhanced, but cell-mediated immunity is insufficient for cancer and allergy therapy
Solution Approach 1:
The patent changes the immunological parameter profile by combining two different adjuvant mechanisms (CpG ODN and STING agonist) that together shift the immune response from Th2-dominant to Th1-dominant. This parameter change enables simultaneous achievement of humoral immunity enhancement and cell-mediated immunity induction, making the adjuvant suitable for cancer and allergy therapies
Data Source
AI summary
The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.